[{"id":"db802908-d352-4788-a1a5-ab4e959f4c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03009240","created_at":"2024-03-12T22:20:15.146Z","updated_at":"2024-07-02T16:35:15.595Z","phase":"Phase 1","brief_title":"Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia","source_id_and_acronym":"NCT03009240","lead_sponsor":"City of Hope Medical Center","biomarkers":" MIR155 • NFKB1","pipe":" | ","alterations":" miR-155 expression • NFKB1 expression","tags":["MIR155 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e miR-155 expression • NFKB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/21/2017","start_date":" 08/21/2017","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-03-08"},{"id":"ebeeadce-a5b3-4e8b-a248-5925a2749718","acronym":"","url":"https://clinicaltrials.gov/study/NCT00389805","created_at":"2021-01-18T01:21:26.551Z","updated_at":"2024-07-02T16:37:05.692Z","phase":"Phase 1/2","brief_title":"Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors","source_id_and_acronym":"NCT00389805","lead_sponsor":"University of California, Davis","biomarkers":" BCL2 • BCL2L1 • NFKB1","pipe":" | ","alterations":" BCL2 expression • NFKB1 expression","tags":["BCL2 • BCL2L1 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • NFKB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 03/01/2005","start_date":" 03/01/2005","primary_txt":" Primary completion: 12/01/2006","primary_completion_date":" 12/01/2006","study_txt":" Completion: 06/01/2007","study_completion_date":" 06/01/2007","last_update_posted":"2018-10-31"},{"id":"2b2f0343-2fdc-402e-ac31-cc0aacd84b59","acronym":"","url":"https://clinicaltrials.gov/study/NCT01955395","created_at":"2021-01-18T08:52:24.780Z","updated_at":"2024-07-02T16:37:24.351Z","phase":"","brief_title":"Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma","source_id_and_acronym":"NCT01955395","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" SDC1","pipe":" | ","alterations":" NFKB1 expression","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NFKB1 expression"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2017-03-16"}]